Home/X4 Pharmaceuticals/Adam Craig, MD, PhD, MBA

AC

Adam Craig, MD, PhD, MBA

Executive Chair

X4 Pharmaceuticals

Therapeutic Areas

Rare Immune Disorders Hematology

X4 Pharmaceuticals Pipeline

Drug	Indication	Phase
XOLREMDI (mavorixafor)	WHIM Syndrome	Approved
Mavorixafor	Chronic Neutropenic Disorders	Phase 3

Leadership Team at X4 Pharmaceuticals

President, Chief Operating Officer

Chief Financial Officer

Gary J. Bridger, PhD

View full X4 Pharmaceuticals profile